journal
MENU ▼
Read by QxMD icon Read
search

Cancer Treatment Reviews

journal
https://www.readbyqxmd.com/read/29287242/checkpoint-inhibitors-in-breast-cancer-current-status
#1
REVIEW
Anne Polk, Inge-Marie Svane, Michael Andersson, Dorte Nielsen
INTRODUCTION: An increasing number of compounds directed against immune checkpoints are currently under clinical development. In this review we summarize current research in breast cancer. MATERIAL AND METHODS: A computer-based literature search was carried out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were included as well. RESULTS: The obtained overall response rate of PD-1/PD-L1 monotherapy varied from 5 to 30% in heavily pretreated triple negative breast cancer (TNBC)...
December 14, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29275224/staging-and-surgical-approaches-in-gastric-cancer-a-systematic-review
#2
REVIEW
Natalie Coburn, Roxanne Cosby, Laz Klein, Gregory Knight, Richard Malthaner, Joseph Mamazza, C Dale Mercer, Jolie Ringash
BACKGROUND: Gastric adenocarcinoma accounted for 6.8% of new cancer cases and 8.8% of cancer deaths worldwide in 2012. Although resection is the cornerstone for cure, several aspects of surgical intervention remain controversial or sub-optimally applied at the population level. These include staging, extent of lymph node dissection (LND), optimal requirements of LN assessment, minimum resection margins, surgical technique (laparoscopic vs. open), relationship between surgical volumes and patient outcomes, and resection of stage IV gastric cancer...
December 13, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29272781/a-systematic-review-of-the-effectiveness-of-patient-based-educational-interventions-to-improve-cancer-related-pain
#3
REVIEW
Wendy H Oldenmenger, Jenske I Geerling, Irina Mostovaya, Kris C P Vissers, Alexander de Graeff, Anna K L Reyners, Yvette M van der Linden
BACKGROUND: Despite existing guidelines to assess and manage pain, the management of cancer-related pain is often suboptimal with patients often being undertreated. Inadequate pain management may be due to patient-related barriers. Educating patients may decrease these barriers. However, the effect of pain education on patient-related outcomes is still unclear. This review aimed to study the effect of educational interventions on cancer-related pain. DESIGN: We performed a systematic review of randomized controlled trials (RCTs) identified from Medline and Cinahl, from 1995 to May 2017...
December 13, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29276997/cancer-immunotherapy-in-a-neglected-population-the-current-use-and-future-of-t-cell-mediated-checkpoint-inhibitors-in-organ-transplant-patients
#4
REVIEW
Young Kwang Chae, Carlos Galvez, Jonathan F Anker, Wade T Iams, Manali Bhave
Although the indications for immune checkpoint inhibitors continue to grow, organ transplant recipients with advanced malignancies have been largely excluded from clinical trials testing the safety and efficacy of these therapies given their need for chronic immunosuppression and the risk of allograft rejection. With the rapid growth of transplant medicine and the increased risk of malignancy associated with chronic immunosuppression, it is critical that we systematically analyze the available data describing immune checkpoint blockade in the organ transplant population...
December 8, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29329006/ongoing-unmet-needs-in-treating-estrogen-receptor-positive-her2-negative-metastatic-breast-cancer
#5
REVIEW
Gül A Başaran, Chris Twelves, Véronique Diéras, Javier Cortés, Ahmad Awada
Estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) is the most common MBC subtype and currently remains incurable, with a median overall survival of 24.8 months (95% confidence interval, 21.3-30.3). Common sites of metastases are bone, viscera, and brain, causing significant symptoms that negatively affect patient functioning, quality of life (QoL), and work productivity. Guidelines state that endocrine therapy (ET) is preferable to chemotherapy as first-line treatment for patients with ER+ MBC, regardless of limited visceral metastases, unless rapid tumor response is required or ET resistance is suspected...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29304463/management-of-qt-prolongation-induced-by-anti-cancer-drugs-target-therapy-and-old-agents-different-algorithms-for-different-drugs
#6
REVIEW
Carmela Coppola, Anna Rienzo, Giovanna Piscopo, Antonio Barbieri, Claudio Arra, Nicola Maurea
The side effects of anticancer drugs still play a critical role in survival and quality of life. Although the recent progresses of cancer therapies have significantly improved the prognosis of oncologic patients, side effects of antineoplastic treatments are still responsible for the increased mortality of cancer survivors. Cardiovascular toxicity is the most dangerous adverse effect induced by anticancer therapies. A survey conducted by the National Health and Nutrition Examination, showed that 1807 cancer survivors followed up for seven years: 51% died of cancer and 33% of heart disease (Vejpongsa and Yeh, 2014)...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29253837/aiming-for-the-insulin-like-growth-factor-1-system-in-breast-cancer-therapeutics
#7
REVIEW
Panagiotis F Christopoulos, Alexandre Corthay, Michael Koutsilieris
Despite the major discoveries occurred in oncology the recent years, breast malignancies remain one of the most common causes of cancer-related deaths for women in developed countries. Development of HER2-targeting drugs has been considered a breakthrough in anti-cancer approaches and alluded to the potential of targeting growth factors in breast cancer (BrCa) therapeutics. More than twenty-five years have passed since the Insulin-like Growth Factor-1 (IGF-1) system was initially recognized as a potential target candidate in BrCa therapy...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29253836/multi-agent-chemotherapy-in-advanced-soft-tissue-sarcoma-sts-a-systematic-review-and-meta-analysis
#8
REVIEW
Alona Zer, Rebecca M Prince, Eitan Amir, Albiruni R Abdul Razak
BACKGROUND: Despite a lack of improvement in overall survival (OS) with doxorubicin-based combinations over doxorubicin alone in advanced STS, the role of multi-agent chemotherapy remains poorly defined. METHODS: We conducted a systematic review and meta-analysis to evaluate benefits and harms of multi-agent chemotherapy in advanced STS. Eligible studies were randomized trials of chemotherapy in advanced STS comparing single agent to multi-agent therapy. Data from studies reporting a hazard ratio (HR) and 95% confidence intervals (CI) for OS and progression-free survival (PFS) were pooled in a meta-analysis...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29247978/advances-in-chromosomal-translocations-and-fusion-genes-in-sarcomas-and-potential-therapeutic-applications
#9
REVIEW
Xin Xiao, Cassandra C Garbutt, Francis Hornicek, Zheng Guo, Zhenfeng Duan
Chromosomal translocations and fusion genes are very common in human cancer especially in subtypes of sarcomas, such as rhabdomyosarcoma, Ewing's sarcoma, synovial sarcoma and liposarcoma. The discovery of novel chromosomal translocations and fusion genes in different tumors are due to the advancement of next-generation sequencing (NGS) technologies such as whole genome sequencing. Recently, many novel chromosomal translocations and gene fusions have been identified in different types of sarcoma through NGS approaches...
December 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29223828/rationale-for-combination-of-therapeutic-antibodies-targeting-tumor-cells-and-immune-checkpoint-receptors-harnessing-innate-and-adaptive-immunity-through-igg1-isotype-immune-effector-stimulation
#10
REVIEW
Robert L Ferris, Heinz-Josef Lenz, Anna Maria Trotta, Jesús García-Foncillas, Jeltje Schulten, François Audhuy, Marco Merlano, Gerard Milano
Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity (ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment for locally advanced and recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic colorectal cancer (CRC). Here we review evidence regarding the clinical relevance of cetuximab-mediated ADCC and other immune functions and provide a biological rationale concerning why this property positions cetuximab as an ideal partner for immune checkpoint inhibitors (ICIs) and other emerging immunotherapies...
December 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29207310/cxcl9-cxcl10-cxcl11-cxcr3-axis-for-immune-activation-a-target-for-novel-cancer-therapy
#11
REVIEW
Ryuma Tokunaga, Wu Zhang, Madiha Naseem, Alberto Puccini, Martin D Berger, Shivani Soni, Michelle McSkane, Hideo Baba, Heinz-Josef Lenz
Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis)...
November 26, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29197746/proton-therapy-for-locally-advanced-breast-cancer-a-systematic-review-of-the-literature
#12
REVIEW
Emmanuel Kammerer, Jennifer Le Guevelou, Abdulhamid Chaikh, Serge Danhier, Julien Geffrelot, Christelle Levy, Eric Saloux, Jean-Louis Habrand, Juliette Thariat
BACKGROUND: Radiation therapy plays a major role in the management of adjuvant breast cancer with nodal involvement, with an iatrogenic increase of cardio-vascular risk. Photon therapy, even with intensity modulation, has the downsides of high mean heart dose and heterogeneous target coverage, particularly in the case of internal mammary irradiation. This systematic review of the literature aims to evaluate proton therapy in locally advanced breast cancer. MATERIAL AND METHODS: PubMed was searched for original full-text articles with the following search terms: «Proton Therapy» and «Breast Cancer»...
November 24, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29202445/balancing-the-benefits-and-harms-of-thyroid-cancer-surveillance-in-survivors-of-childhood-adolescent-and-young-adult-cancer-recommendations-from-the-international-late-effects-of-childhood-cancer-guideline-harmonization-group-in-collaboration-with-the-pancaresurfup
#13
REVIEW
S C Clement, L C M Kremer, F A Verburg, J H Simmons, M Goldfarb, R P Peeters, E K Alexander, E Bardi, E Brignardello, L S Constine, C A Dinauer, V M Drozd, F Felicetti, E Frey, A Heinzel, M M van den Heuvel-Eibrink, S A Huang, T P Links, K Lorenz, R L Mulder, S J Neggers, E J M Nieveen van Dijkum, K C Oeffinger, R R van Rijn, S A Rivkees, C M Ronckers, A B Schneider, R Skinner, J D Wasserman, T Wynn, M M Hudson, P C Nathan, H M van Santen
Radiation exposure to the thyroid gland during treatment of childhood, adolescent and young adult cancer (CAYAC) may cause differentiated thyroid cancer (DTC). Surveillance recommendations for DTC vary considerably, causing uncertainty about optimum screening practices. The International Late Effects of Childhood Cancer Guideline Harmonization Group, in collaboration with the PanCareSurFup Consortium, developed consensus recommendations for thyroid cancer surveillance in CAYAC survivors. These recommendations were developed by an international multidisciplinary panel that included 33 experts in relevant medical specialties who used a consistent and transparent process...
November 14, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29197745/cancer-chemoprevention-revisited-cytochrome-p450-family-1b1-as-a-target-in-the-tumor-and-the-microenvironment
#14
REVIEW
Gabriele D'Uva, Denisa Baci, Adriana Albini, Douglas M Noonan
Cancer chemoprevention is the use of synthetic, natural or biological agents to prevent or delay the development or progression of malignancies. Intriguingly, many phytochemicals with anti-inflammatory and anti-angiogenic effects, recently proposed as chemoprevention strategies, are inhibitors of Cytochrome P450 family 1B1 (CYP1B1), an enzyme overexpressed in a wide variety of tumors and associated with angiogenesis. In turn, pro-inflammatory cytokines were reported to boost CYP1B1 expression, suggesting a key role of CYP1B1 in a positive loop of inflammatory angiogenesis...
November 11, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29190505/advances-in-sarcoma-gene-mutations-and-therapeutic-targets
#15
REVIEW
Peng Gao, Nicole A Seebacher, Francis Hornicek, Zheng Guo, Zhenfeng Duan
Sarcomas are rare and complex malignancies that have been associated with a poor prognostic outcome. Over the last few decades, traditional treatment with surgery and/or chemotherapy has not significantly improved outcomes for most types of sarcomas. In recent years, there have been significant advances in the understanding of specific gene mutations that are important in driving the pathogenesis and progression of sarcomas. Identification of these new gene mutations, using next-generation sequencing and advanced molecular techniques, has revealed a range of potential therapeutic targets...
November 11, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29175677/efficacy-and-safety-of-regorafenib-in-the-treatment-of-metastatic-colorectal-cancer-a-systematic-review
#16
REVIEW
Maria Røed Skårderud, Anne Polk, Kirsten Kjeldgaard Vistisen, Finn Ole Larsen, Dorte Lisbet Nielsen
PURPOSE: Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited. Regorafenib was approved in 2012 for the treatment of patients with metastatic colorectal cancer previously treated with approved standard therapy. The purpose of this review is to present existing clinical data on regorafenib. METHOD: We systematically searched the PubMed and Embase databases, as well as ASCO and ESMO conference abstracts, for studies in English including ≥30 patients, evaluating the efficacy and safety of regorafenib in patients with metastatic colorectal cancer...
November 10, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29121502/the-prognostic-role-of-epigenetic-dysregulation-in-bladder-cancer-a-systematic-review
#17
REVIEW
David Casadevall, Anaïs Yacine Kilian, Joaquim Bellmunt
BACKGROUND: Despite adequate treatment and follow-up, around one fifth of patients with localized bladder cancer will present with disease progression. Adequate prognostic biomarkers are lacking to define patients who are at risk. Mutations in chromatin remodeling genes are more frequently found in bladder cancer than in any other solid tumor. However, the prognostic relevance of epigenetic dysregulation has not been established and may offer an opportunity for biomarker discovery. METHODS: Looking for prognostic epigenetic factors, we performed a comprehensive PubMed search using keywords such as "bladder cancer", "chromatin remodeling", "gene methylation" and "epigenetics"...
November 6, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29154022/the-anti-tumor-effect-of-rankl-inhibition-in-malignant-solid-tumors-a-systematic-review
#18
REVIEW
A F de Groot, N M Appelman-Dijkstra, S H van der Burg, J R Kroep
At present, accumulating evidence suggests that inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) does not only induce an increase in bone mass and strength, but also has anti-tumor effects. Denosumab, an antibody targeting RANKL, is used to treat osteoporosis and to prevent skeletal related events (SREs) in patients with bone metastases originating from solid tumors. However, expression of RANKL and its receptor activator of nuclear factor kappa-B (RANK) is not solely restricted to cells involved in homeostasis of the bone and RANKL-RANK signalling appears to play a substantial role in many other processes in the body like mammary physiology, mammary tumorigenesis and the immune system...
November 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29108713/risk-of-adverse-events-with-the-addition-of-targeted-agents-to-endocrine-therapy-in-patients-with-hormone-receptor-positive-metastatic-breast-cancer-a-systematic-review-and-meta-analysis
#19
REVIEW
Samuel Martel, Marco Bruzzone, Marcello Ceppi, Christian Maurer, Noam Falbel Ponde, Arlindo R Ferreira, Giulia Viglietti, Lucia Del Mastro, Catherine Prady, Evandro de Azambuja, Matteo Lambertini
BACKGROUND: Combining targeted agents and endocrine therapy (ET) improves outcomes in hormone receptor-positive metastatic breast cancer patients but increases the risk of adverse events (AEs). This meta-analysis aims to estimate the comparative risk of AEs with ET in addition to targeted agents in this setting. METHODS: A systematic literature search of MEDLINE, EMBASE, Cochrane Library and conference proceedings up to July 17th 2017 was conducted to identify randomized controlled trials investigating ET with or without CDK4/6, mTOR, PI3K inhibitors and anti-HER2 agents...
October 28, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29202431/triple-negative-breast-cancer-emerging-therapeutic-modalities-and-novel-combination-therapies
#20
REVIEW
Alice Lee, Mustafa B A Djamgoz
Triple negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer which lacks oestrogen receptors, progesterone receptors and HER2 amplification, thereby making it difficult to target therapeutically. In addition, TNBC has the highest rates of metastatic disease and the poorest overall survival of all breast cancer subtypes. Resultantly, development of targeted therapies for TNBC is urgently needed. Recent efforts aimed at molecular characterisation of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins...
January 2018: Cancer Treatment Reviews
journal
journal
25655
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"